$ARMP News

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate

Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?

Why Is Armata Pharma Stock Gaining Monday?

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

Armata Pharma Promotes David House To CFO

Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia

Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

Armata Pharma Receives Additional $2.5M Of Non-Dilutive DoD Funding Via Medical Technology Enterprise Consortium, Managed By Naval Medical Research Command

Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

Armata Pharmaceuticals Q1 EPS $(3.16) Misses $(0.38) Estimate, Sales $789.000K Up From $491.000K YoY

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

Armata Pharmaceuticals Granted FDA's Fast Track Designation For AP-SA02 To Treat Bacterial Infections

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

Armata Pharmaceutics Announces Publication Of Paper In 'Communications Biology,' A Peer-Reviewed Journal From Nature Portfolio

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results